Mieloencefalitis protozoaria equina en un equino en Colombia: reporte de caso

Equine Protozoal Myeloencephalitis (EPM) is an infectious neurological disease with a high percentage of mortality that affects equines that share habitat with their definitive host; however, it has not been widely reported in endemic regions. In Colombia, a country with wide distribution of the host, a veterinarian is consulted for a clinical case of an equine with neurological and muscular symptoms compatible with EPM. Antibiotic and anticoccidial treatment was immediately initiated when this pathology is suspected, and a blood sample was sent to confirm the diagnosis in the laboratory. The sample was positive for the sarcocystin toxin produced by the protozoan S. neurona. The equine responded positively and fully recovered five months after treatment. This case report shows the importance of taking this pathology into account as a differential diagnosis to establish an effective treatment as soon as possible, generating a favourable prognosis and, therefore, a recovery for the patient.La Mieloencefalitis Protozoaria Equina (EPM) es una enfermedad neurológica infecciosa con alto porcentaje de mortalidad que afecta a los equinos que comparten hábitat con su hospedero definitivo; sin embargo no ha sido muy reportada en regiones endémicas. En Colombia, país de amplia distribución del hospedero, es consultado un médico veterinario por un caso clínico de un equino con sintomatología neurológica y muscular compatible con EPM. Se inicia tratamiento con antibiótico y anticoccidial ante la sospecha de esta patología y remite una muestra de sangre para confirmar el diagnóstico en el laboratorio. La muestra fue positiva a la toxina sarcocistina producida por el protozoo S. neurona. El equino respondió positivamente y se recuperó totalmente a los cinco meses del tratamiento. Este reporte evidencia la importancia de tener en cuenta esta patología como diagnóstico diferencial con el fin de instaurar un tratamiento eficaz lo antes posible generando un pronóstico favorable y, por ende, una recuperación del paciente

Efectos de la fatiga sobre la actividad muscular durante sucesivos test de sentadilla (30 seg).

Resumen:  Introducción: La fatiga se define como la incapacidad del Sistema neuromuscular para mantener un nivel determinado de potencia. La monitorización de la pérdida de Altura de salto ha sido utilizada como un indicador de fatiga muscular. La Electromiografía (EMG) es también una herramienta adecuada para determinar la fatiga ya que tiene una alta correlación con las unidades motoras activas (reclutamiento de fibras musculares). El objetivo del presente estudio es evaluar los efectos de la fatiga sobre la actividad muscular en las extremidades inferiores durante sucesivos test de media sentadilla (30 segundos). Métodos: 5 sujetos sanos entrenados participaron en el estudio. Realizaron 2 sesiones de test, un test de potencia máxima de media sentadilla y 4 series de un test de capacidad anaeróbica de media sentadilla (30 seg.). Resultados: Se observaron diferencias significativas (P=0.002) en la comparativa de los efectos inter-sujetos (Vasto lateral vs. Recto femoral). Observamos también diferencias significativas en la comparación por pares (P<0.001). Conclusiones: Observamos cómo la fatiga modifica la activación neuromuscular del vasto lateral y el recto femoral durante la ejecución de 4 test consecutivos de media sentadilla (30 seg.).Peer Reviewe

Uso de un simulador bovino para prácticas de palpación transrectal

The aim of this study was to determine the efficiency of a bovine simulator for transrectal palpation practices. A commercial bovine simulator and four non-pregnant bovine females were used. The study included 20 and 22 students without experience in transrectal palpation who participated in the experimental (I) and control (II) group, respectively. The students of group I were trained with the simulator for the location of cervix, uterus and ovaries, while those of group II received a traditional practice, consisting of working with reproductive tracts in situ. Then, both groups were evaluated by two expert instructors in four cows regarding the correct location of the anatomical structures. The Chi square test determined differences in the degree of accuracy of the recognition of the anatomical structures between groups (p&lt;0.05), having a better level of recognition of the structures in the experimental group, which indicated the utility of the simulator for the identification of the cervix, uterus and ovaries in transrectal palpation practices.El objetivo del estudio fue determinar la eficiencia de un simulador bovino para prácticas de palpación transrectal. Se utilizó un simulador bovino comercial y cuatro hembras bovinas no gestantes. Se trabajo con 20 y 22 estudiantes sin experiencia en la técnica de palpación transrectal que participaron como grupo experimental (I) y control (II), respectivamente. Los estudiantes del grupo I fueron entrenados con el simulador para la ubicación de cérvix, útero y ovarios, mientras que los del grupo II recibieron una práctica tradicional, consistente en el trabajo con tractos reproductivos in situ. Luego, ambos grupos fueron evaluados por dos palpadores expertos en cuatro bovinos respecto a la correcta ubicación de las estructuras anatómicas. La prueba de Chi cuadrado determinó diferencias en el grado de precisión del reconocimiento de las estructuras anatómicas entre grupos (p&lt;0.05), habiendo un mejor nivel de reconocimiento de las estructuras en el grupo experimental, indicando la utilidad del simulador para la identificación de la cérvix, útero y ovarios en las prácticas de palpación transrectal

Restos de caballos fósiles cuaternarios en la depresión Prados-Guatén (Pantoja de la Sagra, Toledo)

Durante la primera reunión de campo del Grupo Madrileño de Cuaternario (GQM-AEQUA) se localizaron restos fragmentarios de dentición de caballos fósiles en los antiguos areneros de Pantoja de La Sagra (Toledo), actualmente en proceso de desmantelamiento y relleno. Ante la posibilidad de deterioro y pérdida los restos fueron recolectados y trasladados al Museo Nacional de Ciencias Naturales (CSIC, Madrid) donde se ha procedido a su análisis. Las piezas fósiles analizadas responden a un maxilar izquierdo con tres piezas dentales in situ (molares y premolares), y otras siete más aisladas. Todos los dientes aislados, junto con el fragmento de maxilar existente, corresponden a un adulto joven. Los restos fósiles se encontraban asociados a un nivel de arenas fluviales situado unos cuatro metros por debajo de la superficie de la Terraza de +15 m de la Depresión Prados-Guatén definida como un nivel perteneciente al tránsito Pleistoceno inferior-medio, del antiguo Sistema fluvial Manzanares-Guatén por Silva (1988). En concreto los niveles superiores de esta terraza han sido interpretados como resultado de la superposición de los últimos depósitos del antiguo sistema fluvial y los primeros asociados al relleno de la Depresión por tributarios de área fuente más local tras su abandono como consecuencia del proceso de captura del valle inferior del Manzanares por parte del Río Jarama al SW de la Ciudad de Madrid (Silva et al., 1988). Los caracteres morfológicos y morfométricos de las piezas dentarias permiten identificarlos como Equus ferus cf. mosbachensis cuya distribución bioestratigráfica abarca la parte final del Pleistoceno Medio (c.a. 500-200 ka B.P.). Junto a los restos fósiles aparecieron también escasos fragmentos líticos correspondientes a productos de lascado en sílex de difícil atribución tecnológica. Los restos fósiles analizados, indican que el depósito extensivo de arenas fluviales en el eje de la Depresión, culminó durante el final del Pleistoceno medio, y que la dinámica fluvial de la Depresión tras su proceso de abandono fue de hecho más activa de lo que se pensaba con la instalación de sistemas de arroyos relevantes alimentados por cabeceras locales antes del encajamiento definitivo actual de los arroyos Prados y Guatén.Peer reviewe

Correction : Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10, 2885

The authors wish to make the following corrections to this paper [...]

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain : Large-Scale Epidemiological Study

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31-56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

CIBERER : Spanish national network for research on rare diseases: A highly productive collaborative initiative

Altres ajuts: Instituto de Salud Carlos III (ISCIII); Ministerio de Ciencia e Innovación.CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Multicines, escuela de cine y sede de la Semana Internacional de Cine de Valladolid [Hojas Resumen]

Multicines, escuela de cine y sede de la semana internacional de cine de Valladoli